New Sickle Cell Treatment Deemed a Success
A clinical trial of hydroxyurea therapy for children with sickle cell anemia has been halted a year early by the U.S. National Heart, Lung and Blood Institute (NHLBI), because results show hydroxyurea therapy is a safe and effective way to manage the disease and reduce the risk of stroke.
Early results showed that hydroxyurea “works as well as blood transfusions which lowers the risk of the child having a stroke,” said principal investigator Dr. Russell Ware, director of hematology at Cincinnati Children’s.
Cincinnati Children’s was the sponsoring institution in the study, with 25 medical centers in the United States and Canada also participating.
Learn more about sickle cell anemia in children and the study at HealthDay.com.